Medbase, 114 Milton Avenue, Chapel Hill, NC, 27514, USA.
Department of Cell Biology, Faculty of Science and BIOCEV, Charles University, Prague, Czech Republic.
Br J Cancer. 2019 Oct;121(7):513-514. doi: 10.1038/s41416-019-0536-0. Epub 2019 Aug 20.
Novel androgen deprivation agents delay metastasis in non-metastatic, castration-resistant, prostate cancer (nmCRPC). The recent regulatory guidance: considerations for metastasis-free survival endpoint in clinical trials, opens new opportunities in cell biology, medicinal chemistry and advanced imaging. Past failures are the likely result of equating tumour shrinkage to efficacy, rather than inhibition of tumour spread. In the future, the selection of anti-metastasis drug candidates will probably be based on anti-migratory rather than anti-proliferative potential. Oligometastatic cancer coupled with advanced imaging can serve as a clinical proof-of-concept model.
新型雄激素剥夺剂可延缓非转移性去势抵抗性前列腺癌（nmCRPC）的转移。最近的监管指导意见：临床试验中无转移生存终点的考虑因素，为细胞生物学、药物化学和先进成像技术开辟了新的机会。过去的失败很可能是因为将肿瘤缩小等同于疗效，而不是抑制肿瘤扩散。未来，抗转移药物候选物的选择可能将基于抗迁移而非抗增殖潜能。寡转移性癌症结合先进的成像技术可以作为临床概念验证模型。
